TDC
ALDR

Thompson Davis & Co’s Alder Biopharmaceuticals ALDR Stock Holding History

Thompson Davis & Co’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-125
Closed -$1K – 776
2017
Q4 		$1K Sell
125
-250
-67% -$2.79K ﹤0.01% 655
2017
Q3 		$5K Buy
+375
New +$3.91K 0.01% 869
2016
Q1 		– Sell
-250
Closed -$8K – 1214
2015
Q4 		$8K Sell
250
-500
-67% -$16.9K 0.01% 733
2015
Q3 		$25K Sell
750
-250
-25% -$10.6K 0.04% 406
2015
Q2 		$53K Buy
+1,000
New +$36.4K 0.06% 299

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Thompson Davis & Co's ALDR Position: Q1 2018 in Review

Thompson Davis & Co sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 125 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in ALDR in Q2 2015 and held it in 5 quarters. The position peaked at $53K in Q2 2015. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Thompson Davis & Co reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Alder Biopharmaceuticals shares in Q1 2018, an estimated $1K.
  • Thompson Davis & Co first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 5 quarters.
  • Thompson Davis & Co's Alder Biopharmaceuticals position peaked at $53K in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Thompson Davis & Co's 13F filing for Q1 2018, filed 2 May 2018.